These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Luo L; Shi HZ; Liang QL; Jiang J; Qin SM; Deng JM Respir Med; 2010 Jan; 104(1):149-56. PubMed ID: 19945835 [TBL] [Abstract][Full Text] [Related]
27. Association of biomarker levels with severity of asbestos-related diseases. Park EK; Yates DH; Creaney J; Thomas PS; Robinson BW; Johnson AR Saf Health Work; 2012 Mar; 3(1):17-21. PubMed ID: 22953226 [TBL] [Abstract][Full Text] [Related]
28. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. Hollevoet K; Van Cleemput J; Thimpont J; De Vuyst P; Bosquée L; Nackaerts K; Germonpré P; Vansteelandt S; Kishi Y; Delanghe JR; van Meerbeeck JP J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346 [TBL] [Abstract][Full Text] [Related]
29. Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma. Fukuoka K; Kuribayashi K; Yamada S; Tamura K; Tabata C; Nakano T Mol Clin Oncol; 2013 Nov; 1(6):942-948. PubMed ID: 24649274 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases. Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V; Franko A Radiol Oncol; 2020 Mar; 54(1):86-95. PubMed ID: 32187018 [TBL] [Abstract][Full Text] [Related]
31. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Hollevoet K; Nackaerts K; Thas O; Thimpont J; Germonpré P; De Vuyst P; Bosquée L; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP Chest; 2012 Feb; 141(2):477-484. PubMed ID: 21737491 [TBL] [Abstract][Full Text] [Related]
32. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560 [TBL] [Abstract][Full Text] [Related]
33. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819 [TBL] [Abstract][Full Text] [Related]
34. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232 [TBL] [Abstract][Full Text] [Related]
36. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Creaney J; Robinson BW Hematol Oncol Clin North Am; 2005 Dec; 19(6):1025-40, v. PubMed ID: 16325121 [TBL] [Abstract][Full Text] [Related]
37. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. Weber DG; Taeger D; Pesch B; Kraus T; Brüning T; Johnen G Cancer Biomark; 2007; 3(6):287-92. PubMed ID: 18048966 [TBL] [Abstract][Full Text] [Related]
38. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916 [TBL] [Abstract][Full Text] [Related]
39. [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma]. Amati M; Tomasetti M; Scartozzi M; Mariotti L; Ciuccarelli M; Valentino M; Governa M; Santarelli L G Ital Med Lav Ergon; 2007; 29(3 Suppl):335-8. PubMed ID: 18409713 [TBL] [Abstract][Full Text] [Related]
40. Follow-up of Soluble Mesothelin-Related Protein Levels in Participants With Asbestos-Related Disorders. Park EK; Johnson AR; Wilson D; Thomas PS; Yates DH Saf Health Work; 2020 Dec; 11(4):425-430. PubMed ID: 33329908 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]